Abstract:Transcriptionally latent forms of replication-competent proviruses, present primarily in a small subset of memory CD4 + T cells, pose the primary barrier to a cure for HIV-1 infection because they are the source of the viral rebound that almost inevitably follows the interruption of antiretroviral therapy. Over the last 30 years, many of the factors essential for initiating HIV-1 transcription have been identified in studies performed using transformed cell lines, such as the Jurkat T-cell model. However, as highlighted in this review, several poorly understood mechanisms still need to be elucidated, including the molecular basis for promoter-proximal pausing of the transcribing complex and the detailed mechanism of the delivery of P-TEFb from 7SK snRNP. Furthermore, the central paradox of HIV-1 transcription remains unsolved: how are the initial rounds of transcription achieved in the absence of Tat? A critical limitation of the transformed cell models is that they do not recapitulate the transitions between active effector cells and quiescent memory T cells. Therefore, investigation of the molecular mechanisms of HIV-1 latency reversal and LRA efficacy in a proper physiological context requires the utilization of primary cell models. Recent mechanistic studies of HIV-1 transcription using latently infected cells recovered from donors and ex vivo cellular models of viral latency have demonstrated that the primary blocks to HIV-1 transcription in memory CD4 + T cells are restrictive epigenetic features at the proviral promoter, the cytoplasmic sequestration of key transcription initiation factors such as NFAT and NF-κB, and the vanishingly low expression of the cellular transcription elongation factor P-TEFb. One of the foremost schemes to eliminate the residual reservoir is to deliberately reactivate latent HIV-1 proviruses to enable clearance of persisting latently infected cells—the "Shock and Kill" strategy. For "Shock and Kill" to become efficient, effective, non-toxic latency-reversing agents (LRAs) must be discovered. Since multiple restrictions limit viral reactivation in primary cells, understanding the T-cell signaling mechanisms that are essential for stimulating P-TEFb biogenesis, initiation factor activation, and reversing the proviral epigenetic restrictions have become a prerequisite for the development of more effective LRAs.

Transforming Growth Factor β Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4 + T Cells

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Identification of CD98 As a Novel Biomarker for HIV-1 Permissiveness and Latent Infection

Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies

Gp120 Binding with DC-SIGN Induces Reactivation of HIV-1 Provirus Via the NF-κB Signaling Pathway

Role of DC-SIGN Induced Signaling Pathway in the Activation of HIV-1 Virus

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Transforming growth factor-β promotes the function of HIV-specific CXCR5+ CD8 T cells

The cell biology of HIV-1 latency and rebound

FBXO34 Promotes Latent HIV-1 Activation by Post-Transcriptional Modulation

Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/beta-catenin/TCF1 axis in CD4(+) T cells

Microbiome and Metabolome driven differentiation of TGF-β producing Tregs leads to Senescence and HIV latency

Post-Transcriptional HIV-1 Latency: A Promising Target for Therapy?

T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin

TSC1 and DEPDC5 regulate HIV-1 latency through the mTOR signaling pathway.

TGF-β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo

The Upregulation of Lag-3 on T Cells Defines A Subpopulation with Functional Exhaustion and Correlates with Disease Progression in Hiv-Infected Subjects